Abstract Number: 1687 • ACR Convergence 2025
Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
Background/Purpose: SLE predominantly affects women and is often accompanied by physical changes and psychological distress. Although both body image dissatisfaction and sexual dysfunction are reported…Abstract Number: 1543 • ACR Convergence 2025
Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Background/Purpose: Patients with both Type 2 diabetes mellitus (T2DM) and systemic lupus erythematosus (SLE) face an increased risk of cardiovascular complications due to the compounding…Abstract Number: 1526 • ACR Convergence 2025
Guidance For Corticosteroid Tapering In Patients With Systemic Lupus Erythematosus: Results From An International Delphi Consensus Project
Background/Purpose: Despite guidelines for SLE emphasizing the importance of tapering corticosteroids (CS), detailed recommendations on how to taper are limited. The purpose of this modified…Abstract Number: 1502 • ACR Convergence 2025
Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune, chronic disorder characterized by multi-system organ involvement. The hepatic involvement in SLE is categorized as a primary…Abstract Number: 1485 • ACR Convergence 2025
Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune condition presenting with unpredictable varying levels of severity. Thus, constant monitoring of disease activity is…Abstract Number: 1469 • ACR Convergence 2025
Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
Background/Purpose: In systemic lupus erythematosus (SLE), differences have been observed between patients of different ages at onset. This study evaluates remission, low disease activity, and…Abstract Number: 1277 • ACR Convergence 2025
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…Abstract Number: 1082 • ACR Convergence 2025
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…Abstract Number: 0946 • ACR Convergence 2025
A Novel Preclinical Tool for Evaluating CD20 Antibody Efficacy Based on BAFF/CD20 Dual-target Humanized Mice
Background/Purpose: CD20, a well characterized B-cell surface marker involved in B-cell activation and differentiation, plays a critical role in the pathogenesis of B-cell mediated diseases…Abstract Number: 0908 • ACR Convergence 2025
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Background/Purpose: Abnormal cell surface glycosylation has been observed in various autoimmune diseases, including systemic lupus erythematosus (SLE) and membranous nephropathy. Among these glycan modifications, sialoglycans…Abstract Number: 0653 • ACR Convergence 2025
In Vitro Pharmacological Profile of GLPG3667 Suggests Differentiation from the TYK2 Inhibitors Deucravacitinib and Zasocitinib at their Clinical Dose Regimens
Background/Purpose: Tyrosine kinase 2 (TYK2), a Janus kinase (JAK) family member, is attracting a lot of interest as a new target to treat patients with…Abstract Number: 0632 • ACR Convergence 2025
Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with a heightened risk of cardiovascular and renal complications, particularly in patients with comorbid diabetes mellitus. While both…Abstract Number: 0614 • ACR Convergence 2025
Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…Abstract Number: 0598 • ACR Convergence 2025
Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases
Background/Purpose: HCQ induced cardiomyopathy leading to heart failure is a rare but serious potential treatment complication. Currently there are no screening guidelines for detecting HCQ…Abstract Number: 0804 • ACR Convergence 2025
Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus
Background/Purpose: Belimumab is a monoclonal antibody targeting B-lymphocyte stimulator (BLyS) used in the treatment of active systemic lupus erythematosus (SLE). Our objective was to investigate…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 181
- Next Page »